vs
Apellis Pharmaceuticals, Inc.（APLS）与芯科实验室（SLAB）财务数据对比。点击上方公司名可切换其他公司
芯科实验室的季度营收约是Apellis Pharmaceuticals, Inc.的1.0倍（$208.2M vs $199.9M），芯科实验室同比增速更快（25.2% vs -5.9%），芯科实验室自由现金流更多（$-1.6M vs $-14.3M），过去两年芯科实验室的营收复合增速更高（39.9% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
芯科实验室（Silicon Labs）是一家全球无晶圆厂科技企业，专注于设计、生产半导体及其他硅基器件并提供配套软件，产品与方案面向全球物联网基础设施领域的电子设计工程师及制造商供应。
APLS vs SLAB — 直观对比
营收规模更大
SLAB
是对方的1.0倍
$199.9M
营收增速更快
SLAB
高出31.2%
-5.9%
自由现金流更多
SLAB
多$12.7M
$-14.3M
两年增速更快
SLAB
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $208.2M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | 63.4% |
| 营业利润率 | -25.6% | -1.6% |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | 25.2% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $-0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSSLAB
| Q1 26 | — | $208.2M | ||
| Q4 25 | $199.9M | $206.0M | ||
| Q3 25 | $458.6M | $192.8M | ||
| Q2 25 | $178.5M | $177.7M | ||
| Q1 25 | $166.8M | — | ||
| Q4 24 | $212.5M | $166.2M | ||
| Q3 24 | $196.8M | $166.4M | ||
| Q2 24 | $199.7M | $145.4M |
净利润APLSSLAB
| Q1 26 | — | — | ||
| Q4 25 | $-59.0M | $-9.9M | ||
| Q3 25 | $215.7M | $-21.8M | ||
| Q2 25 | $-42.2M | — | ||
| Q1 25 | $-92.2M | — | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $-28.5M | ||
| Q2 24 | $-37.7M | $-82.2M |
毛利率APLSSLAB
| Q1 26 | — | 63.4% | ||
| Q4 25 | — | 57.8% | ||
| Q3 25 | — | 56.1% | ||
| Q2 25 | — | 55.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 54.3% | ||
| Q3 24 | — | 54.3% | ||
| Q2 24 | — | 52.7% |
营业利润率APLSSLAB
| Q1 26 | — | -1.6% | ||
| Q4 25 | -25.6% | -6.0% | ||
| Q3 25 | 48.7% | -11.9% | ||
| Q2 25 | -18.6% | -18.1% | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | -17.2% | ||
| Q3 24 | -24.0% | -17.9% | ||
| Q2 24 | -14.7% | -33.0% |
净利率APLSSLAB
| Q1 26 | — | — | ||
| Q4 25 | -29.5% | -4.8% | ||
| Q3 25 | 47.0% | -11.3% | ||
| Q2 25 | -23.6% | — | ||
| Q1 25 | -55.3% | — | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | -17.1% | ||
| Q2 24 | -18.9% | -56.5% |
每股收益（稀释后）APLSSLAB
| Q1 26 | — | $-0.07 | ||
| Q4 25 | $-0.40 | $-0.30 | ||
| Q3 25 | $1.67 | $-0.67 | ||
| Q2 25 | $-0.33 | $-0.94 | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | $-0.72 | ||
| Q3 24 | $-0.46 | $-0.88 | ||
| Q2 24 | $-0.30 | $-2.56 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $443.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.1B |
| 总资产 | $1.1B | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSSLAB
| Q1 26 | — | $443.6M | ||
| Q4 25 | $466.2M | $439.0M | ||
| Q3 25 | $479.2M | $415.5M | ||
| Q2 25 | $370.0M | $424.8M | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | $382.2M | ||
| Q3 24 | $396.9M | $369.7M | ||
| Q2 24 | $360.1M | $339.2M |
股东权益APLSSLAB
| Q1 26 | — | $1.1B | ||
| Q4 25 | $370.1M | $1.1B | ||
| Q3 25 | $401.2M | $1.1B | ||
| Q2 25 | $156.3M | $1.1B | ||
| Q1 25 | $164.2M | — | ||
| Q4 24 | $228.5M | $1.1B | ||
| Q3 24 | $237.1M | $1.1B | ||
| Q2 24 | $264.3M | $1.1B |
总资产APLSSLAB
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $821.4M | $1.2B | ||
| Q1 25 | $807.3M | — | ||
| Q4 24 | $885.1M | $1.2B | ||
| Q3 24 | $901.9M | $1.2B | ||
| Q2 24 | $904.5M | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $8.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-1.6M |
| 自由现金流率自由现金流/营收 | -7.1% | -0.8% |
| 资本支出强度资本支出/营收 | 0.1% | 4.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $65.8M |
8季度趋势，按日历期对齐
经营现金流APLSSLAB
| Q1 26 | — | $8.3M | ||
| Q4 25 | $-14.2M | $34.3M | ||
| Q3 25 | $108.5M | $4.9M | ||
| Q2 25 | $4.4M | $48.1M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.4M | $10.1M | ||
| Q3 24 | $34.1M | $31.6M | ||
| Q2 24 | $-8.3M | $16.1M |
自由现金流APLSSLAB
| Q1 26 | — | $-1.6M | ||
| Q4 25 | $-14.3M | $27.9M | ||
| Q3 25 | $108.3M | $-3.8M | ||
| Q2 25 | $4.4M | $43.3M | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | $6.2M | ||
| Q3 24 | — | $29.4M | ||
| Q2 24 | $-8.4M | $12.6M |
自由现金流率APLSSLAB
| Q1 26 | — | -0.8% | ||
| Q4 25 | -7.1% | 13.6% | ||
| Q3 25 | 23.6% | -2.0% | ||
| Q2 25 | 2.5% | 24.4% | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | 3.7% | ||
| Q3 24 | — | 17.7% | ||
| Q2 24 | -4.2% | 8.7% |
资本支出强度APLSSLAB
| Q1 26 | — | 4.8% | ||
| Q4 25 | 0.1% | 3.1% | ||
| Q3 25 | 0.0% | 4.5% | ||
| Q2 25 | 0.0% | 2.7% | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | 2.4% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.0% | 2.4% |
现金转化率APLSSLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
SLAB
| Sales Channel Through Intermediary | $157.5M | 76% |
| Sales Channel Directly To Consumer | $50.7M | 24% |
